SFRP1 Attenuates Oral Submucous Fibrosis via Wnt/β-Catenin Inhibition

Study Background and Research Question

Oral submucous fibrosis (OSF) is a chronic, progressive condition marked by excessive collagen deposition and fibrosis in the oral mucosa, often resulting in restricted mouth opening and a high risk of malignant transformation. The disease is particularly prevalent in Asian populations, closely linked to areca nut chewing, and carries substantial morbidity and mortality rates. Current therapies are largely conservative, focusing on symptom alleviation rather than disease modification. Recent advances have highlighted the importance of the immune microenvironment, especially neutrophil infiltration, in OSF pathology. Additionally, aberrant activation of the Wnt/β-catenin signaling pathway has been implicated in fibrogenesis across multiple tissues. However, the precise interplay between immune cell recruitment, Wnt signaling, and fibrosis in OSF remains insufficiently defined. This study, therefore, sought to clarify the mechanistic role of secreted frizzled-related protein 1 (SFRP1)—a known antagonist of Wnt signaling—in OSF progression and tissue remodeling according to the reference study.

Key Innovation from the Reference Study

The principal innovation of this research is its demonstration that SFRP1 acts as a molecular brake on OSF pathology by simultaneously reducing neutrophil infiltration and inhibiting the Wnt/β-catenin pathway. While SFRP1 has previously been recognized as a Wnt antagonist and tumor suppressor in various tissues, its dual role in modulating both immune cell invasion and fibrotic signaling within the oral mucosa had not been established. This dual mechanism was elucidated using an arecoline-induced mouse model of OSF, which allowed for direct assessment of collagen deposition, immune infiltration, and Wnt pathway activation in situ.

Methods and Experimental Design Insights

The investigators developed a robust OSF mouse model by administering arecoline, a principal alkaloid of the areca nut, to induce fibrotic changes in oral mucosal tissue. Using Pearson’s correlation analysis, they evaluated the relationship between SFRP1 expression levels, Wnt/β-catenin pathway activity, and neutrophil infiltration. Immunohistochemical and biochemical assays quantified key protein markers, including β-catenin, Cyclin D1, and c-myc, alongside markers of neutrophil presence and collagen deposition. Crucially, the effects of SFRP1 overexpression were assessed both in vivo and in vitro: in mice, SFRP1 was overexpressed systemically, while in cellular models, a Wnt/β-catenin pathway activator was used to probe the reversibility of SFRP1’s effects on fibrogenesis. This multi-modal approach enabled mechanistic dissection of signaling crosstalk and immune cell dynamics within the fibrotic microenvironment.

Core Findings and Why They Matter

The study found that OSF induction led to pronounced collagen deposition and increased neutrophil infiltration within the oral mucosal tissue, accompanied by elevated activity of the Wnt/β-catenin pathway. SFRP1 expression was significantly reduced in OSF tissues compared to healthy controls, and negatively correlated with both Wnt/β-catenin protein levels and neutrophil infiltration. When SFRP1 was overexpressed, there was a marked decrease in both neutrophil recruitment and tissue fibrosis, as well as downregulation of β-catenin, Cyclin D1, and c-myc. These anti-fibrotic and immunomodulatory effects were reversed by application of a Wnt/β-catenin pathway activator in vitro, confirming that SFRP1’s action was mediated through inhibition of this pathway. Collectively, these results position SFRP1 as a critical suppressor of the inflammatory and fibrogenic cascades that drive OSF progression, underscoring the potential of Wnt/β-catenin modulation as a targeted intervention strategy.

Comparison with Existing Internal Articles

Internal resources reinforce and contextualize these findings. For example, an internal review describes how SFRP1-mediated suppression of Wnt/β-catenin signaling reduces both fibrosis and immune cell infiltration in OSF models, aligning with the reference study’s mechanistic conclusions. Similarly, another summary highlights the dual anti-fibrotic and immunosuppressive roles of SFRP1, emphasizing the importance of Wnt pathway regulation in oral fibrogenesis. These internal perspectives further support the notion that targeting the Wnt/β-catenin axis—either by antagonism (as with SFRP1) or controlled activation (as in developmental studies)—can provide key mechanistic insights and translational potential for both fibrotic and regenerative research. Notably, research compounds such as HLY78 have been employed in related studies to precisely modulate the Wnt/β-catenin pathway, enabling researchers to dissect signaling mechanisms in embryogenesis and fibrosis with high specificity.

Limitations and Transferability

While the findings are robust within the context of an arecoline-induced mouse model, several limitations should be acknowledged. First, the precise molecular intermediates linking SFRP1 to neutrophil recruitment require further elucidation. Second, the translatability of these results to human OSF and other fibrotic oral pathologies awaits validation in clinical or primary tissue studies. The study also does not address potential compensatory mechanisms or the effects of chronic Wnt/β-catenin modulation on oral mucosal homeostasis. Lastly, the use of a single pathway activator in vitro may not fully recapitulate the complexity of in vivo signaling environments. Despite these caveats, the strategic targeting of Wnt/β-catenin signaling remains a promising research avenue for understanding and potentially mitigating OSF and related fibrotic diseases.

Protocol Parameters

• Arecoline induction: Administered to mice to establish OSF; concentration and dosing as per referenced protocols.
• SFRP1 overexpression: Delivered via suitable vector or transgenic approach; verify efficiency through immunohistochemistry or western blot.
• Wnt/β-catenin pathway activator application (in vitro): Add to OSF cell models post-SFRP1 overexpression to assess pathway reversibility.
• Assessment endpoints: Collagen deposition (histology), β-catenin/Cyclin D1/c-myc protein levels (western blot/IHC), neutrophil infiltration (marker staining), and SFRP1 quantification.

Research Support Resources

For researchers seeking to modulate Wnt/β-catenin signaling in fibrosis or embryonic development models, HLY78 (SKU C5433) is a well-characterized small-molecule positive modulator that acts in a ligand-dependent manner by targeting the Axin DIX domain and enhancing downstream signaling. This compound has demonstrated utility as a zebrafish embryogenesis Wnt activator and for the induction of hematopoietic stem cell markers such as cmyb and runx1, and is available from APExBIO for research use. For detailed mechanistic studies or to model fibrotic signaling reversibility, HLY78 can be incorporated into established workflows alongside SFRP1 modulation strategies, as highlighted in both the reference and supporting internal articles.